Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study

<b>Background</b>: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6 i), abemaciclib, palbociclib, and ribociclib, have been FDA-approved for the treatment of hormone receptor-positive (HR+), HER2−negative (HER2−) advanced breast cancer (aBC). This targeted therapy has revived hope in those...

Full description

Bibliographic Details
Main Authors: Alberto D’Angelo, Fabiola Giudici, Robert Chapman, Jacob Darlow, Huseyin Kilili, Navid Sobhani, Mattia Cinelli, Maria Rosa Cappelletti, Carla Strina, Manuela Milani, Daniele Generali
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Current Issues in Molecular Biology
Subjects:
breast cancer
metastasis
CDK4/6 inhibitors
immunomodulation
Online Access:https://www.mdpi.com/1467-3045/44/9/292

Internet

https://www.mdpi.com/1467-3045/44/9/292

Similar Items